14.58
price down icon6.54%   -1.02
after-market Dopo l'orario di chiusura: 14.71 0.13 +0.89%
loading

Kalvista Pharmaceuticals Inc Borsa (KALV) Ultime notizie

pulisher
11:23 AM

What analysts say about KalVista Pharmaceuticals Inc. stock outlookPhenomenal capital gains - jammulinksnews.com

11:23 AM
pulisher
09:54 AM

New medicines recommended for approval by EMA’s CHMP - The Pharma Letter

09:54 AM
pulisher
09:34 AM

What analysts say about KalVista Pharmaceuticals Inc. stockFree Daily Trading Room Entry - Autocar Professional

09:34 AM
pulisher
09:23 AM

KalVista receives CHMP opinion recommending sebetralstat marketing authorization - TipRanks

09:23 AM
pulisher
09:23 AM

KalVista, Biogen, Ionis get EU positive opinions for key drugs (KALV:NASDAQ) - Seeking Alpha

09:23 AM
pulisher
08:38 AM

European regulator recommends approval of first oral HAE treatment - Investing.com India

08:38 AM
pulisher
08:31 AM

KalVista Pharma Announces Positive CHMP Opinion For Sebetralstat - Nasdaq

08:31 AM
pulisher
08:00 AM

KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks - Business Wire

08:00 AM
pulisher
06:53 AM

What drives KalVista Pharmaceuticals Inc. stock priceFree Daily Trading Room Entry - PrintWeekIndia

06:53 AM
pulisher
Jul 24, 2025

US FDA Cancer Reviewers Heading For The Exits, Potentially Impacting Review Timelines - insights.citeline.com

Jul 24, 2025
pulisher
Jul 23, 2025

KalVista Pharmaceuticals Inc. Stock Analysis and ForecastRobust investment performance - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Is KalVista Pharmaceuticals Inc. a good long term investmentRapid return acceleration - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Friedreich's Ataxia Market Is Expanding Due To Advancing - openPR.com

Jul 21, 2025
pulisher
Jul 17, 2025

Kalvista Pharmaceuticals stock maintains Market Outperform rating at JMP By Investing.com - Investing.com South Africa

Jul 17, 2025
pulisher
Jul 17, 2025

Kalvista Pharmaceuticals stock maintains Market Outperform rating at JMP - Investing.com India

Jul 17, 2025
pulisher
Jul 16, 2025

(KALV) Proactive Strategies - news.stocktradersdaily.com

Jul 16, 2025
pulisher
Jul 16, 2025

JMP reiterates Market Outperform rating on Kalvista stock after UK approval By Investing.com - Investing.com South Africa

Jul 16, 2025
pulisher
Jul 16, 2025

JMP reiterates Market Outperform rating on Kalvista stock after UK approval - Investing.com Nigeria

Jul 16, 2025
pulisher
Jul 16, 2025

KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema - BioSpace

Jul 16, 2025
pulisher
Jul 15, 2025

KalVista Pharmaceuticals Gets UK Approval for Hereditary Angioedema Treatment - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

KalVista Pharmaceuticals announces UK MHRA approval of Ekterly (sebetralstat) - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

KalVista gets UK nod for Ekterly (KALV:NASDAQ) - Seeking Alpha

Jul 15, 2025
pulisher
Jul 15, 2025

UK approves first oral treatment for hereditary angioedema attacks By Investing.com - Investing.com Canada

Jul 15, 2025
pulisher
Jul 15, 2025

(sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema - Business Wire

Jul 15, 2025
pulisher
Jul 15, 2025

MHRA approves Ekterly to treat HAE - The Pharma Letter

Jul 15, 2025
pulisher
Jul 15, 2025

KalVista Pharmaceuticals Wins UK Approval for Hereditary Angioedema Treatment - MarketScreener

Jul 15, 2025
pulisher
Jul 14, 2025

Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga

Jul 14, 2025
pulisher
Jul 13, 2025

Have Insiders Sold KalVista Pharmaceuticals Shares Recently? - simplywall.st

Jul 13, 2025
pulisher
Jul 13, 2025

The week in pharma: action, reaction and insight – week to July 11 - The Pharma Letter

Jul 13, 2025
pulisher
Jul 11, 2025

Kalvista stock maintains Buy rating at H.C. Wainwright on favorable Ekterly label - Investing.com Nigeria

Jul 11, 2025
pulisher
Jul 11, 2025

KalVista:HC Wainwright Raises PT to $27, Maintains Buy Rating - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Kalvista Pharma chief development officer sells $474k in shares By Investing.com - Investing.com Canada

Jul 11, 2025
pulisher
Jul 10, 2025

KalVista Pharmaceuticals: EKTERLY Launch and Financial Update - TipRanks

Jul 10, 2025
pulisher
Jul 10, 2025

Kalvista Pharma chief development officer sells $474k in shares - Investing.com Australia

Jul 10, 2025
pulisher
Jul 10, 2025

Kalvista Pharma CEO Palleiko sells $517k in shares By Investing.com - Investing.com South Africa

Jul 10, 2025
pulisher
Jul 10, 2025

Kalvista Pharma CEO Palleiko sells $517k in shares - Investing.com Australia

Jul 10, 2025
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Capitalizzazione:     |  Volume (24 ore):